Article Text

Download PDFPDF
Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlCrossRefPubMedWeb of Science

Q What is the efficacy of higher doses of venlafaxine extended release compared with standard doses for treating adults with major depressive disorder who do not respond or cannot tolerate selective serotonin reuptake inhibitor therapy?


Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:

Not clear.

Embedded ImageBlinding:

Open label.

Embedded ImageFollow up period:

Twelve weeks (treatment period only).

Embedded ImageSetting:

Twenty two outpatient sites in the USA; time period not stated.

Embedded ImagePatients:

232 adult outpatients (mean age 43) with major depressive disorder (Structured Clinical Interview for DSM-IV) and a score ⩾14 on the 21 item Hamilton Depression Rating scale (HAM-D21) who had not previously taken venlafaxine. Participants had to have a lack of response or inability to tolerate an adequate trial of a selective serotonin reuptake inhibitor (SSRI) during their current depressive episode, within the …

View Full Text


  • For correspondence: Michael E Thase MD, Department of Psychiatry, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA; thaseme{at}

  • Source of funding: Wyeth Pharmaceuticals.